November 2023

Risque d'événements cardiovasculaires majeurs chez les patients atteints de polyarthrite rhumatoïde et traités par des antirhumatismaux synthétiques conventionnels, biologiques et synthétiques ciblés : Données d'observation du registre allemand RABBIT

RMD Open 2023;9:e003489 doi 10.1136/rmdopen-2023-003489

This study by Meissner, et al. estimated the effects of JAKi, TNFi, bDMARDs and csDMARDs on the risk of MACE in RA patients. The authors found no significant difference in MACE risk by treatment group, even among patients at increased CV risk.

Keywords:

Traitement par JAK inhibiteurs ou bDMARDs et risque d'événements cardiovasculaires dans la population néerlandaise de la polyarthrite rhumatoïde

Rheumatology (Oxford) 2023 doi 10.1093/rheumatology/kead531 Epub ahead of print

This retrospective inception cohort study investigated RA patients starting a new bDMARD or JAKi prescription between 01 August 2018 and 31 January 2022 from IQVIA’s Dutch Real-World Data Longitudinal Prescription database.

Keywords:

Efficacité et sécurité du tofacitinib chez les patients atteints de spondylarthrite ankylosante en fonction de la prise antérieure d'antirhumatismaux modificateurs de la maladie : Une analyse post hoc

ACR Open Rheumatol. 2023;5(12)632–643 doi 10.1002/acr2.11601

In this post hoc analysis by Deoodhar, et al., the authors found that tofacitinib demonstrated greater efficacy than placebo in bDMARD-naïve and TNFi-IR AS patients. They also found that safety event rates for tofacitinib therapy were numerically higher in the TNFi-IR subgroup than the bDMARD-naïve subgroup.

Keywords:

October 2023

Traitement par le bimekizumab chez des patients naïfs de DMARD biologiques atteints de rhumatisme psoriasique actif : résultats d'efficacité et de sécurité à 52 semaines de l'étude BE OPTIMAL de phase III, randomisée, contrôlée par placebo et à référence active

Ann Rheum Dis. 2023;82(11):1404–1414 doi: 10.1136/ard-2023-224431

Data from this phase 3 RCT demonstrated that the efficacy of bimekizumab observed at 16 weeks remained consistent through to 52 weeks in the treatment of bDMARD-naïve patients with PsA. Patients who started the trial on placebo and switched to bimekizumab at week 16 showed similar improvements to those patients who were randomised to receive bimekizumab at the start of the trail. No new safety signals were identified.

Keywords:

Traitement par Upadacitinib dans le rhumatisme psoriasique actif : Données d'efficacité et de sécurité des 192 premiers patients de l'étude UPJOINT, une étude observationnelle multicentrique en pratique clinique

Rheumatol Ther. 2023;10(6):1503–1508 doi: 10.1007/s40744-023-00589-3

In the UPJOINT open label study, the proportion of patients with PsA, and an inadequate response to csDMARDs or bDMARDs, who achieved minimal disease activity with upadacitinib was in line with the results of previous studies at 24 weeks. No new safety signals were identified.

Keywords:

Efficacité et sécurité de l'Upadacitinib chez les patients atteints de spondylarthrite ankylosante réfractaire aux traitements biologiques : résultats à un an de l'extension ouverte d'une étude de phase III

Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1

The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.

Keywords:

August 2023

Le pipeline 2023 des médicaments antirhumatismaux modificateurs de la maladie (DMARD) en développement clinique pour la spondylarthrite (y compris le rhumatisme psoriasique) : Une revue systématique des essais

RMD Open. 2023;9(3):e003279 doi 10.1136/rmdopen-2023-003279 https://pubmed.ncbi.nlm.nih.gov/37507210/

This systematic review identified DMARDs evaluated for axSpA and PsA, distinguishing between csDMARDs, tsDMARDs, and bDMARDs. The review pinpointed twenty-six distinct targeted therapies currently in clinical development; 18 therapies for axSpA and 15 therapies for PsA.

Keywords:

July 2023

Effet de l'Upadacitinib sur l'activité de la maladie, la douleur, la fatigue, la fonction, la qualité de vie liée à la santé et la productivité au travail dans la spondylarthrite ankylosante réfractaire aux agents biologiques

Rheumatol Ther 2023; 10:679–91 doi 10.1007/s40744-023-00536-2

Upadacitinib significantly improved patient-reported outcomes in AxSpA patients with bDMARD-IR after 14 Weeks of treatment. There were notable improvements in disease activity, pain, fatigue, function, HRQoL, and work productivity.

Keywords:

May 2023

Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study

Int JMol Sci 2023;24(8):6967 doi 10.3390/ijms24086967

A prospective observational study showed that recombinant zoster vaccine (RZV) immunogenicity is not impaired in RA patients on JAK inhibitors or anti-cellular bDMARDs.

Keywords:

April 2023

Association Between Biological Immunotherapy for Psoriasis and Time to Incident Inflammatory Arthritis: A Retrospective Cohort Study

Lancet Rheumatol 2023;5:200–207 doi https://doi.org/10.1016/S2665-9913(23)00034-6

Retrospective cohort study found 15 501 PsO patients in the TriNetX database during January 2014–June 2022 that were prescribed bDMARDS, of which 6.3% developed inflammatory arthritis. 3.5% of all patients in the study specifically developed PsA.